Becton Dickinson

Becton Dickinson

Becton Dickinson, incorporated in New Jersey and headquartered in Franklin Lakes, operates as one of the world's largest pure-play medical technology companies. The firm traces its roots to 1897, when Maxwell Becton and Fairleigh Dickinson founded a medical supply import business that would evolve into the diagnostics and devices giant known today. BD's investment activity is conducted through both its corporate venture arm and its corporate development function, which evaluates acquisitions, minority stakes, and strategic partnerships across the healthcare continuum. The company's deployment strategy centers on three primary segments. BD Medical covers medication management, drug delivery systems, and pharmaceutical systems — areas where BD has made venture investments in connected injection devices and digital adherence platforms. BD Life Sciences encompasses integrated diagnostic solutions, specimen collection, and biosciences, with confirmed investment interests in single-cell genomics and microbiology automation. BD Interventional addresses surgery, peripheral intervention, and urology through both organic development and bolt-on acquisitions. The firm's geographic footprint spans the Americas, Europe, and Asia-Pacific, with particular emphasis on China, Japan, and emerging markets for diagnostic access programs. BD operates with a workforce exceeding 70,000 employees and maintains a balance sheet that supports both internal R&D investment and external capital deployment. The company's corporate venture group, BD Ventures, typically participates in Series A through growth-stage rounds with check sizes ranging from $5 million to $25 million, often syndicating with traditional life-sciences venture firms. In April 2024, BD announced it had completed the separation of its Diabetes Care business as a standalone public company called Embecta, a structural move that freed capital and management attention for its higher-growth segments. BD's structural differentiator is the combination of a captive distribution channel into nearly every US hospital and health system with a corporate venture mandate that can offer startups not just capital but immediate commercialization pathways. Portfolio companies gain access to BD's regulatory affairs expertise, manufacturing scale, and global sales infrastructure — a sourcing model that gives BD Ventures a proprietary deal flow advantage over standalone healthcare VCs.